PD-1inhibitor

DRUG5 trials

Conditions

Esophageal Squamous Cell CarcinomaGastric CancerGastroesophageal Junction CancerHNSCCNeoadjuvant ChemoradiotherapyPD-1RadiotherapyUnresectable Locally Advanced Esophageal Cancer

Phase 1

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

RecruitingNCT06173986

Shanghai Chest HospitalEsophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer

Start: 2023-01-10End: 2027-12-30Target: 50Updated: 2023-12-18

Phase 2

Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction

RecruitingNCT06250894

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyGastroesophageal Junction Cancer, Neoadjuvant Chemoradiotherapy, PD-1

Start: 2021-03-30End: 2025-03-30Target: 32Updated: 2024-02-09

PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)

Not yet recruitingNCT07090707

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHNSCC, PD-1, Radiotherapy

Start: 2025-08-01End: 2031-12-31Target: 50Updated: 2025-07-29

Phase 3

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy

RecruitingNCT05980715

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHNSCC, PD-1, Radiotherapy

Start: 2023-01-01End: 2030-12-31Target: 324Updated: 2023-08-08

Unknown Phase

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

RecruitingNCT06417892

Cancer Institute and Hospital, Chinese Academy of Medical SciencesGastric Cancer

Start: 2024-04-15End: 2026-12-30Target: 60Updated: 2025-01-14

Related Papers

571. A PHASE I/II MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT IMMUNO-CHEMORADIOTHERAPY IN UNRESECTABLE LA-ESCC

Diseases of the Esophagus2024-09-01